Status:
COMPLETED
C1 Inhibitor Registry in the Treatment of Hereditary Angioedema (HAE) Attacks
Lead Sponsor:
Pharming Technologies B.V.
Conditions:
Hereditary Angioedema
Eligibility:
All Genders
Brief Summary
This is a non-interventional treatment Registry of Hereditary Angioedema (HAE) patients treated with C1 inhibitor, either plasma-derived (pdC1INH) or the recombinant human form (rhC1INH / Ruconest), t...
Detailed Description
see below
Eligibility Criteria
Inclusion
- Decision to treat the HAE patient with C1 inhibitor (either Ruconest or pdC1INH)
- Patients must give written informed consent
Exclusion
- A diagnosis of acquired C1INH deficiency (AAE)
Key Trial Info
Start Date :
July 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 10 2024
Estimated Enrollment :
181 Patients enrolled
Trial Details
Trial ID
NCT01397864
Start Date
July 1 2011
End Date
December 10 2024
Last Update
April 8 2025
Active Locations (17)
Enter a location and click search to find clinical trials sorted by distance.
1
UMHAT Alexandrovska EAD
Sofia, Bulgaria
2
KBC Split
Split, Croatia
3
General Hospital Sibenik
Šibenik, Croatia
4
CHC Sestre milosrdnice
Zagreb, Croatia